Waldencast’s Obagi sale creates a debt-free Milk Makeup pure play trading at a steep discount to its clean beauty brand value, but execution, leadership transition, and single-brand concentration remain the key tests.
Waldencast PLC is a beauty and wellness platform currently undergoing a structural transformation from a diversified multi-brand consolidator to a streamlined, pure-play prestige cosmetics operator.[1, 2] The company was founded by consumer staples executives in 2019 and transitioned to public ownership via a special purpose acquisition company (SPAC) merger in July 2022.[3, 4] This business combination brought together two distinct, market-leading beauty assets for a combined transaction value of approximately \$1.2 billion: Obagi Medical, a clinically dispense-focused dermo-cosmetic skincare brand, and Milk Makeup, a high-growth, clean color cosmetics brand.[3, 5, 6]
Historically, Waldencast generated consolidated revenue through these two distinct operating segments, leveraging shared corporate services, cross-border distribution capabilities, and centralized capital allocation.[7, 8] Under this multi-brand structure, the company catered to divergent end markets and customer cohorts:
* The Obagi Medical Segment: This dermo-cosmetic division historically generated the majority of Waldencast’s revenues, dispensing prescription and non-prescription skincare systems directly through dermatologists, plastic surgeons, and aesthetic practitioners, alongside a direct-to-consumer digital portal.[7, 9] The product formulations are engineered to resolve complex clinical skin concerns, including hyperpigmentation, photodamage, skin discoloration, and acne, appealing to patients seeking scientifically backed, regimen-based dermatological solutions.[3, 10]
* The Milk Makeup Segment: Operating in the premium color cosmetics arena, Milk Makeup targets Gen Z and younger Millennial beauty consumers who prioritize clean ingredients, ethical values, and creative self-expression.[11] The brand distributes its extensive lineup of vegan and cruelty-free makeup products through high-profile multichannel retailers, notably Sephora and Ulta Beauty, in addition to direct-to-consumer e-commerce channels.[1, 12, 13]
On June 1, 2026, Waldencast entered into a definitive agreement to sell 100% of the equity interests of Obagi Medical to the private equity firm Bridgepoint for an enterprise value of up to \$460 million.[14, 15] Expected to close in the third quarter of 2026, this transaction fundamentally transforms Waldencast’s strategic profile.[15, 16] Upon completion, the cash proceeds will be deployed to fully repay the company's outstanding \$178 million senior secured term loan facility with Lumina Capital Management, completely de-leveraging the corporate balance sheet and removing significant interest expense headwinds.[15, 16] Post-transaction, Waldencast will operate purely as a single-brand platform focused entirely on scaling and accelerating the global growth of Milk Makeup.[15, 16]
The core value proposition of Milk Makeup, which underpins the post-divestiture investment thesis, lies in its distinct "beautility" design philosophy and its strong position within the clean beauty category.[11, 14] Consumers choose Milk Makeup over mass-market or legacy prestige alternatives due to its highly effective, vegan formulations, unconventional product formats, and deep cultural relevance among younger cohorts.[11, 14, 17] As a public equity vehicle, Waldencast transitions into a debt-free cosmetics operator trading at a significant discount to its intrinsic brand value, presenting a unique opportunity for small-cap equity managers to capture premium beauty assets at a heavily depressed valuation.[16]
The investment thesis for the restructured Waldencast depends on the operational execution and global expansion of Milk Makeup.[15, 16] To assess this potential, the brand's core product portfolio, competitive advantages, market addressability, and competitive landscape must be examined in detail.[8]
Milk Makeup generates revenue through the sale of color cosmetics and skin-prep formulations across more than 300 stock-keeping units (SKUs).[13] All formulas are developed in-house at the brand's downtown New York City creative headquarters, ensuring strict adherence to its 100% vegan, cruelty-free, and clean beauty standards.[13, 17] The brand’s product architecture is organized around high-velocity, high-replenishment product franchises:
* The Hydro Grip Franchise: This collection is the brand's primary revenue driver, anchored by the Hydro Grip Primer, which won the Allure Best of Beauty award.[1, 18] The formulation incorporates blue agave extract, which forms an invisible, tacky physical layer that locks makeup in place for up to 12 hours, alongside hyaluronic acid, aloe water, squalane, and niacinamide to plump and hydrate the skin barrier.[19, 20] This is complemented by the Hydro Grip Set + Refresh Spray and the newly introduced Hydro Grip 12-Hour Hydrating Gel Skin Tint, which offers medium-buildable coverage with a dewy, glass-like finish.[19, 20, 21]
* Complexion and Color Stick Formats: The brand pioneered the multi-benefit solid stick format, designed for convenient, travel-friendly application.[11, 12] Key products include the Lip + Cheek cream color stick, Sculpt Stick bronzers, and the KUSH Mascara, which achieved cult status in the online beauty community for its cannabis seed oil-infused formula designed to condition eyelashes.[17, 18, 19]
* Cooling Water Jelly Tints: Released in 2024, this innovative bouncy jelly lip and cheek stain became highly viral on social media platforms.[4, 19] The water-based formula provides a sheer, buildable stain that dries down quickly to provide long-lasting wear, driving a strong influx of new customers to the brand.[4, 19]
The distribution model is designed as an omnichannel ecosystem.[8, 22] Nationally, the brand is distributed through Sephora (where it was ranked as the number two clean beauty makeup brand in the United States in 2025), over 600 select Ulta Beauty retail stores (expanded in Spring 2025), and Amazon Premium Beauty.[12, 14, 23] Direct-to-consumer e-commerce sales via MilkMakeup.com act as a critical touchpoint to capture high-margin retail transactions and cultivate first-party consumer data.[13, 24]
Milk Makeup maintains a narrow economic moat driven by strong brand equity, high retail distribution barriers, and moderate customer switching costs.[11, 22, 24] Brand equity in prestige cosmetics functions as an emotional and social construct that limits consumer price sensitivity.[11, 22] By centering its marketing on street-culture authenticity, gender-inclusive modeling, and progressive social values, Milk Makeup has built a highly loyal customer base.[11, 18] This strong community affinity supports low customer acquisition costs (CAC) and sustains organic earned media value, protecting the brand from direct price competition from mass-market cosmetics.[11, 22]
Furthermore, physical and digital shelf-space in prestige beauty retailers like Sephora and Ulta is scarce, establishing a structural distribution barrier for newer independent beauty brands.[12, 25, 26] Milk Makeup’s prime retail placements and prominent endcap displays create a defensive competitive position.[12, 25] Finally, a moderate degree of product switching costs exists within consumer makeup regimens.[19] Consumers are typically hesitant to experiment with untested skin primers or setting sprays due to the risk of makeup melting, creasing, or causing skin irritation.[19, 20] Once a consumer integrates the Hydro Grip Primer or Setting Spray into their daily beauty routine, it creates a recurring replenishment cycle that supports stable, high-margin revenue.[8, 19]
Waldencast's opportunity sits at the intersection of the prestige cosmetics market and the clean beauty sector.[26, 27] According to credible industry research:
* The Global Prestige Beauty Market: Valued at approximately \$87.89 billion in 2023, this market is projected to expand at a compound annual growth rate (CAGR) of 5.56% through 2032, driven by premiumization and resilient luxury consumer spending.[26]
* The Global Makeup Market: The global makeup market size reached \$41.23 billion in 2025 and is projected to expand to \$43.48 billion in 2026, on its way to reaching \$54.16 billion by 2030, representing a CAGR of 5.6%.[28, 29]
* Prestige Clean Beauty Trends: In North America and Western Europe, premium cosmetics are experiencing high growth, driven by a structural shift toward clean-label, vegan, and derm-tested formulations.[27, 29] Prestige clean beauty continues to outpace traditional mass-market formulations, placing Milk Makeup in a highly attractive growth segment.[27, 30]
The premium cosmetics market is highly fragmented and contested by three main classes of competitors [22, 31]:
* Mass-Market Dupes: Competitors like e.l.f. Beauty (ELF) utilize a fast-follower model, launching low-priced duplicates of prestige products, such as its Power Grip Primer, which directly targets Milk’s Hydro Grip Primer.[22, 24] e.l.f. operates on a rapid 13-to-20 week concept-to-shelf innovation cycle, putting continuous pressure on prestige pricing.[22, 24]
* Social-Native and Celebrity Prestige Brands: Competitors such as Glossier, Rare Beauty by Selena Gomez, and Fenty Beauty capture significant consumer attention through celebrity founders and exclusive retail partnerships.[22, 31] These brands compete directly with Milk Makeup for millennial and Gen Z discretionary spending and limited retail shelf space.[11, 22]
* Legacy Conglomerates: Global players including L'Oréal (NYX, Urban Decay) and Estée Lauder (MAC, Too Faced) command massive R&D budgets and global distribution networks.[22, 26] While these conglomerates hold substantial market share, they often struggle with agility and clean-beauty credibility among younger demographics, allowing independent, culturally authentic platforms to capture share in prestige clean subcategories.[22, 24]
In terms of market share dynamics, Milk Makeup is holding ground in its core domestic market.[1] In FY 2025, Milk Makeup’s U.S. consumption grew by 6.2%, outperforming the overall U.S. prestige makeup retail sales growth rate of 4.0%.[1] However, on a consolidated global basis, the brand has lost ground due to soft international consumer demand, leading to an 11.4% decline in segment net revenue for FY 2025.[1] Reversing this international sales decline is the primary operational priority for Waldencast’s leadership.[1, 32]
The pending Obagi Medical divestiture significantly alters Waldencast's financial statements, requiring an analysis of both the company's latest quarterly results and the pro-forma valuation of the remaining cosmetics platform.[14, 15, 16]
Waldencast reported its operating and financial results for the first quarter of fiscal year 2026, ended March 31, 2026, on May 25, 2026 via Form 6-K.[33, 34] The company's performance during this period was mixed compared to Wall Street consensus expectations [33]:
* Net Revenue: Reported at \$66.44 million, which beat the analyst consensus forecast of \$65.27 million by 1.79% (a top-line beat of \$1.17 million).[33]
* Earnings Per Share (EPS): Reported at a loss of -\$0.171 per share, missing the analyst consensus estimate of -\$0.150 per share by 14.13% (a bottom-line miss of \$0.021 per share).[33]
* Quarterly Growth Performance: This top-line result of \$66.44 million represents a sequential and year-over-year recovery when compared to the \$65.44 million in net revenue reported in Q1 2025, driven by expanding retail distribution channels for Milk Makeup.[33, 35]
Waldencast announced its audited full-year 2025 results on March 13, 2026, which highlighted stable consolidated revenue but a significant contraction in profit margins and a substantial GAAP net loss [1, 36]:
* Consolidated Net Revenue: \$272.1 million, flat/down 0.7% compared to \$273.9 million in FY 2024.[1]
* Milk Makeup Segment Revenue: \$110.4 million, representing an 11.4% decline compared to \$124.6 million in FY 2024, as solid U.S. market gains were offset by softer international demand.[1]
* Obagi Medical Segment Revenue: \$161.6 million, representing an 8.3% increase from \$149.3 million in FY 2024, supported by direct-to-physician growth and international channels.[1]
* Adjusted Gross Margin: Consolidated adjusted gross margin contracted by 270 basis points to 71.6% (from 74.3% in FY 2024), driven by high holiday promotion levels for Milk Makeup and inventory-related adjustments at Obagi Medical.[1]
* Consolidated Adjusted EBITDA: \$16.1 million (5.9% of Net Revenue), down 60.1% from \$40.3 million in FY 2024, due to margin compression and investments in medical aesthetics injectables.[1]
* GAAP Net Loss: Widened significantly to \$248.1 million (compared to a net loss of \$48.6 million in FY 2024).[1, 36] This loss was primarily driven by non-cash goodwill and intangible asset impairment charges of \$132.1 million on Obagi Medical and \$20.0 million on Milk Makeup, alongside high financing and debt refinancing costs.[1, 36]
Waldencast did not provide a formal financial outlook for the remainder of fiscal year 2026 due to the ongoing strategic review.[1] During recent corporate communications, executive leadership, led by Executive Chairman Felipe Dutra, emphasized three core areas [6, 10, 15]:
* Balance Sheet Optimization: The Up-to-\$460 million Obagi Medical sale enables the company to fully repay its outstanding \$178 million senior secured term loan facility with Lumina Capital Management, completely de-leveraging the public vehicle.[15, 16, 37]
* Operational Pure-Play Focus: The post-transaction business will operate purely as a single-brand cosmetics platform, allowing management to concentrate 100% of corporate resources on accelerating the growth of Milk Makeup.[15, 16]
* International Recovery: Under the leadership of Milk Makeup's President and Co-founder, Mazdack Rassi, the brand is prioritizing marketing investments and distribution channel improvements to reverse international sales declines.[1, 6, 32]
The announcement of the definitive agreement to sell Obagi Medical to Bridgepoint on June 1, 2026, had a significant positive impact on the stock price.[16, 38] On June 1, 2026, Waldencast’s shares surged by 48.78% in standard trading sessions, closing at \$1.83 per share (up from \$1.23 per share on May 29, 2026) on exceptionally high volume of 10.82 million shares.[38]
Following this announcement, sell-side analysts updated their recommendations and target prices [39, 40]:
* On June 2, 2026, Canaccord Genuity analyst Susan Anderson reiterated a "Buy" rating and boosted the 12-month target price from \$2.00 to \$3.00, representing an implied upside of 63.9% relative to the pre-announcement trading price.[39, 41]
* The current Wall Street consensus rating stands at a "Hold" across 4 active analysts, with an average twelve-month target price of \$2.33 (ranging from a low of \$2.00 to a high of \$3.00).[39]
+-------------------------------------------------+
| FY 2025 Consolidated Adjusted EBITDA Bridge |
| (In Thousands) |
+-------------------------------------------------+
GAAP Net Loss $(248,056) [1]
+ Depreciation & Amortization 59,184 [1]
+ Net Interest Expense 25,094 [1]
+ Loss on Extinguishment of Debt 24,398 [1]
+ Goodwill & Intangible Impairments 152,100 [36]
+ Stock-based Compensation 9,011 [1]
+ Strategic Review & Restatement 3,692 [1]
+ Other Adjustments (M&A, FX, Tax) (9,323) [1]
=================================================
Consolidated Adjusted EBITDA $16,100 [1]
The historical segment performance illustrates the strong financial base of Milk Makeup relative to the divested Obagi Medical segment [1]:
| Segment / Metric (In Millions USD) | FY 2025 | FY 2024 | YoY % Change | Margin % (FY 2025) |
|---|---|---|---|---|
| Waldencast Consolidated [1] | ||||
| Net Revenue | \$272.10 | \$273.90 | -0.7% | 100.0% |
| Adjusted Gross Profit | \$194.70 | \$203.60 | -4.3% | 71.6% |
| Adjusted EBITDA | \$16.10 | \$40.30 | -60.1% | 5.9% |
| Obagi Medical (Divested) [1] | ||||
| Net Revenue | \$161.63 | \$149.27 | +8.3% | 100.0% |
| Adjusted Gross Profit | \$123.20 | \$118.60 | +3.9% | 76.2% |
| Adjusted EBITDA | \$19.40 | \$30.50 | -36.3% | 12.0% |
| Milk Makeup (Remaining) [1] | ||||
| Net Revenue | \$110.44 | \$124.60 | -11.4% | 100.0% |
| Adjusted Gross Profit | \$71.50 | \$85.00 | -15.9% | 64.7% |
| Adjusted EBITDA | \$15.20 | \$29.10 | -47.8% | 13.7% |
A pro-forma balance sheet analysis reveals a significant valuation discrepancy.[16] Under the terms of the transaction, Bridgepoint is acquiring Obagi Medical for an enterprise value of up to \$460 million, structured as follows [15, 16]:
* Upfront Cash Consideration: \$366.0 million at closing (subject to customary adjustments).[15, 16]
* Unsecured Vendor Notes: \$30.0 million in principal, comprising a \$10.0 million Fixed Vendor Note and a \$20.0 million Adjustable Vendor Note maturing in 7.5 years.[15, 16]
* Contingent Revenue-Based Earnout: Up to \$64.0 million, tied to Obagi's 2026 non-injectables and 2027 injectables revenue milestones.[15, 16]
At the transaction close, Waldencast will deploy \$178 million of the upfront cash to repay the senior secured term loan in full.[15, 16, 37] Assuming transaction advisory fees, taxes, and working capital adjustments consume approximately \$38.0 million, the pro-forma company will retain approximately \$150.0 million in net cash, with no bank debt on its balance sheet.[16, 37]
At the current trading price of \$1.64 (as of June 17, 2026) and a total ordinary share count of 128,259,872, the equity is valued at a market capitalization of \$210.35 million.[1, 38] This implies a pro-forma Enterprise Value of only \$60.35 million ($\text{Market Capitalization of } \$210.35\text{M} - \text{Net Cash of } \$150.0\text{M}$).[16, 37] Comparing this implied \$60.35 million Enterprise Value to Milk Makeup's standalone FY 2025 revenue of \$110.44 million and Adjusted EBITDA of \$15.20 million highlights an undervalued asset, trading at just 0.55x EV/Sales and 3.97x EV/EBITDA.[15, 16] This significant valuation discount is primarily a legacy of historical debt burdens, internal control weaknesses, and the SEC investigation, all of which have been structurally resolved as of mid-2026.[15, 16, 36, 42]
Evaluating Waldencast as a simplified, pure-play investment vehicle requires analyzing its risk profile across execution, competitive, operational, and macroeconomic dimensions.[2, 16]
The pending transaction requires co-founders Michel Brousset and Hind Sebti, who serve as CEO and Chief Growth Officer, respectively, to exit Waldencast to lead the newly private Obagi Medical in partnership with Bridgepoint.[5, 6, 32] Felipe Dutra, the current Chairman of the Board, is stepping in as Executive Chairman to oversee the transition period.[6, 15, 32] Although Milk Makeup’s daily operations remain under the leadership of brand President and Co-founder Mazdack Rassi, the loss of Waldencast's founding executive team introduces corporate strategy execution risks.[15, 16, 32] Any delay in appointing a permanent, qualified CEO with deep consumer staples experience could slow down product innovation, disrupt retailer relationships, and delay key strategic decisions.[15, 16]
Prestige color cosmetics operate in a highly competitive market susceptible to rapid changes in consumer preferences and marketing trends.[22, 30] The industry has experienced the rise of mass-market "fast beauty" competitors, exemplified by e.l.f. Beauty, which utilize a value-led, digitally native model to launch high-quality alternatives of prestige products at a fraction of the cost.[22, 24] e.l.f.'s successful dupe of Milk's Hydro Grip Primer (sold as the Power Grip Primer) demonstrates how mass-market competitors can capture market share from premium players.[20, 22] To defend its market share, Milk Makeup must sustain high advertising and promotional investments, which can compress gross margins and dilute brand exclusivity.[1, 22]
Following the Obagi divestiture, Waldencast will lose the diversification benefits of its multi-brand platform, exposing investors entirely to the performance of a single brand.[15, 16] Within Milk Makeup, revenue is heavily concentrated in its core Hydro Grip and color stick franchises.[1, 19] Any unexpected deterioration in consumer demand for these core lines would directly impact top-line performance.[1, 19]
Furthermore, the brand faces channel concentration risks due to its reliance on major retail partners Sephora and Ulta Beauty for volume distribution and in-store visibility.[12, 13, 14] Changes in shelf space allocation, retail de-stocking, or changes in Sephora’s clean-beauty rankings represent key risk factors for volume distribution.[14, 35, 43]
While the upfront cash of \$366 million completely de-levers Waldencast, the ultimate equity value of the transaction relies on collecting the remaining \$94.0 million in contingent assets held as vendor notes and earnouts from Bridgepoint.[15, 16] Specifically, the \$30.0 million in Vendor Notes matures in 7.5 years, and the \$64.0 million in earnouts is contingent on Obagi achieving specific 2026-2027 revenue targets under Bridgepoint’s ownership.[15, 16] If Obagi experiences post-acquisition operational disruption or struggles with its newly launched injectables pipeline, Waldencast may fail to collect these earnouts, reducing the cash available for reinvestment.[15, 16]
Historically, Waldencast was impacted by material weaknesses in internal controls and accounting practices, which triggered a formal SEC investigation related to historical restatements at Obagi Cosmeceuticals.[36, 42] While the SEC formally concluded its probe on April 28, 2026, with no recommended enforcement action, the historical internal control material weaknesses remain a corporate governance concern.[36, 42] As a foreign private issuer, Waldencast must prepare to meet Sarbanes-Oxley Section 404 auditor attestation requirements, which could lead to elevated administrative costs and compliance risks.[36, 42]
Prestige beauty is highly sensitive to fluctuations in consumer discretionary spending.[22, 30] During periods of sustained high inflation or economic deceleration, consumer purchasing power contracts, leading beauty shoppers to trade down from premium prestige cosmetics to mass-market drugstore brands.[22, 30] While the premium beauty category historically benefits from the "lipstick effect"—where consumers continue to purchase small, premium discretionary items during downturns—a prolonged recession in North America or Western Europe would impact Milk Makeup's growth trajectory.[22, 27, 30]
This 5-year valuation model projects Waldencast’s financial trajectory from FY 2026 through FY 2031.[33] Pro-forma for the completed Obagi Medical divestiture in Q3 2026, the company's capital structure is assumed to be debt-free, holding an initial net cash balance of \$150.0 million.[15, 16, 37] The model maintains a constant ordinary share count of 128,259,872 shares outstanding.[1]
This scenario assumes Milk Makeup successfully expands its U.S. presence through Ulta and Amazon Premium Beauty while stabilizing its international distribution.[12, 23]
* 5-Year Revenue CAGR: Modeled at 10.0%, with revenue growing from \$110.44 million in FY 2025 to \$177.86 million in FY 2031.[15]
* EBITDA Margin: Expands to 17.5% by Year 5, driven by corporate overhead leverage post-divestiture and supply chain normalization.[1, 15] Year 5 EBITDA is projected at \$31.13 million.
* Exit Valuation Multiple: A conservative EV/EBITDA multiple of 12.0x is applied, which is a discount to fast-growing prestige cosmetics peers.[22]
* Implied Enterprise Value (EV): \$31.13 million * 12.0 = \$373.56 million.
* Balance Sheet Adjustments: Year 5 Net Cash is modeled at \$170.00 million, assuming the collection of \$20.0 million in performance-based earnouts and steady cash generation offset by ongoing brand marketing investments.[15, 16]
* Implied Equity Value: \$373.56 million (EV) + \$170.00 million (Net Cash) = \$543.56 million.
* Projected Share Price (FY 2031): \$4.24.[38]
* 5-Year Total Return: 158.5% (Annualized Return = 20.9%).
This scenario assumes Milk Makeup captures significant market share under Mazdack Rassi’s leadership, accelerating its international rollout and executing high-margin product innovations.[23, 32]
* 5-Year Revenue CAGR: Modeled at 15.0%, with revenue reaching \$222.13 million in FY 2031.[15]
* EBITDA Margin: Expands to 21.0% due to strong pricing power, premium product mix, and global scale.[8] Year 5 EBITDA is projected at \$46.65 million.
* Exit Valuation Multiple: 15.0x EV/EBITDA, reflecting premium market share and accelerated growth.[22]
* Implied Enterprise Value (EV): \$46.65 million * 15.0 = \$699.75 million.
* Balance Sheet Adjustments: Year 5 Net Cash is projected at \$210.00 million, assuming full earnout collection of \$64.0 million, redemption of the \$30.0 million vendor note, and strong operating cash conversion.[15, 16]
* Implied Equity Value: \$699.75 million (EV) + \$210.00 million (Net Cash) = \$909.75 million.
* Projected Share Price (FY 2031): \$7.09.[38]
* 5-Year Total Return: 332.3% (Annualized Return = 34.0%).
This scenario assumes Milk Makeup faces intense competition from mass-market cosmetics brands, and international expansion struggles to gain traction, leading to flat growth and margin compression.[1, 22, 31]
* 5-Year Revenue CAGR: Modeled at 3.0%, with revenue reaching \$128.03 million in FY 2031.[15]
* EBITDA Margin: Contracts to 11.0% due to high promotional requirements and under-rationalized corporate overhead.[1] Year 5 EBITDA is projected at \$14.08 million.
* Exit Valuation Multiple: Contracts to 8.0x EV/EBITDA.[22]
* Implied Enterprise Value (EV): \$14.08 million * 8.0 = \$112.64 million.
* Balance Sheet Adjustments: Net Cash falls to \$110.00 million due to cash burn in international markets and failure to collect any performance-based earnouts.[1, 15, 16]
* Implied Equity Value: \$112.64 million (EV) + \$110.00 million (Net Cash) = \$222.64 million.
* Projected Share Price (FY 2031): \$1.74.[38]
* 5-Year Total Return: 6.1% (Annualized Return = 1.2%).
The share price trajectory and implied returns highlight the strong fundamental base of the post-transaction pure-play business [16, 38]:
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | \$222.13M [15] | 21.0% EBITDA [8] | 15.0x EV/EBITDA | \$1.64 [38] | \$7.09 | 332.3% | 34.0% | 25% |
| Base Case | \$177.86M [15] | 17.5% EBITDA [1] | 12.0x EV/EBITDA | \$1.64 [38] | \$4.24 | 158.5% | 20.9% | 60% |
| Low Case | \$128.03M [15] | 11.0% EBITDA [1] | 8.0x EV/EBITDA | \$1.64 [38] | \$1.74 | 6.1% | 1.2% | 15% |
Based on the assigned probabilities, the weighted valuation target for Waldencast over the 5-year period is \$4.58 per share (derived as $0.25 \times \$7.09 + 0.60 \times \$4.24 + 0.15 \times \$1.74 = \$4.58$), representing an implied total return of 179.3% from the current trading price of \$1.64.[38]
SIGNIFICANT ASSET UNDERVALUATION
This qualitative scorecard evaluates Waldencast’s fundamental positioning post-divestiture, scoring key operational attributes on a scale of 1–10.[15, 16]
Combining these qualitative metrics yields a blended score of 6.0 / 10 for Waldencast, indicating that while structural risks remain, the pending transaction significantly improves the company's financial profile.[15, 16]
Disclaimer: This qualitative scorecard is for analytical purposes and does not constitute financial advice, investment recommendations, or an endorsement to buy or sell securities.
TRANSITION PERIOD AHEAD
The pending divestiture of Obagi Medical to Bridgepoint represents a structural pivot for Waldencast.[15, 16] The transaction transforms the company from a highly leveraged, multi-brand platform with historical regulatory overhangs into a debt-free cosmetics vehicle focused entirely on Milk Makeup.[15, 16, 36, 42]
The core investment thesis is built on three key pillars:
* Unlocking Trapped Equity Value: Pro-forma for the repayment of the \$178 million Lumina Term Loan, Waldencast's Enterprise Value contracts to \$60.35 million relative to its \$150.0 million net cash position.[15, 16] For a brand generating \$110.4 million in sales and \$15.2 million in EBITDA, this represents a significant valuation gap relative to its beauty peers.[15]
* Simplified, Pure-Play Profile: Divesting Obagi removes the operational complexity of managing dermo-cosmetics and injectables alongside color cosmetics.[9, 16, 37] This creates a streamlined, pure-play vehicle for Milk Makeup, which is expected to attract institutional investors.[16]
* Regulatory Resolution: The formal conclusion of the SEC investigation with no enforcement recommended removes a major regulatory overhang, allowing management to focus entirely on operational execution.[37, 42]
Key catalysts include the official transaction closing (expected in Q3 2026), the potential stabilization of international sales, and the successful collection of contingent earnout milestones from Bridgepoint.[15, 16] However, these opportunities must be weighed against transitional executive friction and single-brand concentration risks.[15, 32]
Disclaimer: This analysis is for informational purposes only and does not constitute financial advice, investment recommendations, or an endorsement to buy or sell securities.
DE-LEVERAGED REBIRTH
Waldencast (WALD) is displaying positive technical momentum, currently trading at \$1.64 per share as of June 17, 2026.[38] This places the stock above its 200-day simple moving average of \$1.568, indicating an improving long-term trend.[46] This positive price action was driven by the June 1, 2026, announcement of the Obagi Medical divestiture, which triggered a single-day volume surge and a 48.78% price increase.[16, 38]
In the short term, technical indicators present a neutral-to-bullish outlook as the stock consolidates after hitting a recent pivot high of \$1.98.[38, 46, 47] The conclusion of the SEC investigation with no recommended enforcement has removed a key regulatory overhang, supporting the current price level.[42] The short-term price action is expected to remain supported by the pending Q3 2026 closing of the Obagi transaction, which serves as a major fundamental catalyst.[15, 16]
BULLISH CONSOLIDATION
View Waldencast plc (WALD) stock page
Loading the interactive version of this report…